Eustachian Valve Thrombus and Electrical Cardioversion

Understanding Thromboembolic Risk in Cardioversion

The European Society of Cardiology recommends electrical cardioversion in patients who are hemodynamically compromised by atrial fibrillation when urgent restoration of sinus rhythm is required to improve clinical condition 1
The primary concern with cardioversion is the risk of thromboembolism from left atrial or left atrial appendage thrombi, not right-sided structures, as stated by the European Heart Journal 3, 4
Guidelines specifically mention LAA thrombus as the contraindication to cardioversion, not right-sided thrombi, according to the European Heart Journal 2, 4

Unlike left atrial thrombi, right atrial thrombi, including those on the Eustachian valve, would embolize to the lungs rather than the systemic circulation, as reported in the European Heart Journal 5

Current guidelines focus on left atrial appendage thrombus as the primary concern before cardioversion, as stated by the European Heart Journal 4, 6
Electrical cardioversion is recommended when a decision is made to restore sinus rhythm, provided there is "no evidence of left atrial appendage thrombus", according to the European Heart Journal 1, 2
The absence of LAA thrombus is specifically mentioned in guidelines as the key factor permitting safe cardioversion, as reported in the European Heart Journal 4
No guideline lists Eustachian valve thrombus as a contraindication to cardioversion, as stated by the European Heart Journal and Chest 1, 2, 3

Transesophageal echocardiography is the gold standard for detecting LA/LAA thrombi before cardioversion, as reported in the European Heart Journal 5, 7

Proceed with electrical cardioversion as planned since there is no LAA thrombus, as recommended by the European Heart Journal 1, 2
Ensure the patient is properly anticoagulated before, during, and after the procedure, as stated by Chest and the European Heart Journal 3, 4
For patients undergoing cardioversion, anticoagulation should be continued for at least 4 weeks after successful cardioversion, regardless of baseline stroke risk, as recommended by Chest 3
Long-term anticoagulation decisions should be based on the patient's CHA₂DS₂-VASc score and other stroke risk factors, not on the success of cardioversion, as stated by Chest 3, 8

Monitor for symptoms of pulmonary embolism, which would be the theoretical risk from a right-sided thrombus, as reported in the European Heart Journal 5
Consider follow-up imaging to assess resolution of the Eustachian valve thrombus, as recommended by the European Heart Journal 4
Ensure strict adherence to the prescribed anticoagulation regimen, particularly in the post-cardioversion period, as stated by Chest 8